Novavax, Inc. The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of investors who purchased Novavax, Inc. (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021.
According to the Novavax lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Novavax overstated its manufacturing capabilities and downplayed manufacturing issues that would impact its approval timeline for NVX-CoV2373, a protein-based vaccine candidate engineered from the genetic sequence of the first strain of the SARS-CoV-2 coronavirus; (ii) as a result, Novavax was unlikely to meet its anticipated Emergency Use Authorization regulatory timelines for NVX-CoV2373; (iii) accordingly, the Company overstated the regulatory and commercial prospects for NVX-CoV2373; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Novavax you have until January 11, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
To receive more information, please fill out the form.